Inhibikase Therapeutics Inc
IKT
Company Profile
Business description
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (PD), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Contact
3350 Riverwood Parkway SE
Suite 1900
AtlantaGA30339
USAT: +1 678 392-3419
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.90 | 5.10 | 0.06% |
| CAC 40 | 7,615.97 | 0.02 | -0.00% |
| DAX 40 | 23,587.61 | 53.97 | -0.23% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,762.61 | 3.62 | 0.04% |
| HKSE | 24,474.67 | 297.60 | 1.23% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,942.07 | 151.51 | 0.39% |
| NZX 50 Index | 12,460.96 | 6.52 | -0.05% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,559.20 | 3.70 | 0.04% |
| SSE Composite Index | 3,455.97 | 35.41 | 1.04% |